Intrexon acquired laboratory operations in Budapest, Hungary, from Codexis, which develops biocatalysts for the pharmaceutical and complex chemistry industries. According to Intrexon officials, the deal expands the company’s strain and protein development capabilities, as well as strengthen fermentation process optimization and scaleup. 

“Intrexon’s Industrial Products Division (IPD) will absorb the Budapest lab staff of experienced scientific professionals. Integration of the Budapest team and their expertise with Intrexon’s suite of synthetic biology technologies and capabilities will allow Intrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients (API) and industrial and consumer product collaborations,” said Robert F. Walsh, president of the IPD.

Earlier this week Intrexon signed an agreement with generic drug manufacturer Amneal Pharmaceuticals to develop an improved production process for a complex API. The companies say they will continue to explore other similar opportunities for collaboration in the future.

Previous articleBioethicist Calls for Frank Discussion on Designer Babies
Next articleRIKEN: No Misconduct Yet Found in Its Acid-Bath Stem Cell Investigation